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Purpose or Objective: Radio(chemo)therapy is a crucial 
treatment modality for head and neck squamous cell 
carcinoma (HNSCC). Radiotherapy resistance is a major 
reason for therapy failure and, therefore, predictive 
biomarkers for therapy response are urgently needed. DNA 
gains on chromosome 16q23-24 have been shown to be 
associated with genomic amplification of the FancA gene and 
to correlate with reduced progression-free survival of HNSCC 
patients after radiotherapy. This study aimed to analyze the 
effects of the potential predictive marker FancA on radiation 
sensitivity in vitro, to characterize the underlying molecular 
mechanisms, and to evaluate the clinical relevance in HNSCC. 
 
Material and Methods: We generated FancA overexpressing 
human oral keratinocytes (OKF6/FancA) and analyzed several 
endpoints upon irradiation. To identify signaling pathways 
involved in FancA-mediated resistance, global transcriptome 
analyses were performed after irradiation with 4 Gy or sham-
irradiation followed by pathway enrichment analysis and 
reconstruction of function interaction networks. The clinical 
relevance of the cytogenetic marker 16q23-24, the FancA 
gene and our in vitro results was analyzed in data of 113 
radiotherapy-treated patients from The Cancer Genome Atlas 
(TCGA) HNSCC cohort (Nature, 2015). 
 
Results: Overexpression of FancA resulted in enhanced 
survival after in vitro irradiation. Moreover, FancA 
overexpressing cells demonstrated accelerated DNA damage 
repair mechanisms paralleled by increased repair fidelity: 
enhanced p53 and p21 response, accelerated kinetics in the 
disappearance of γ-H2AX DNA damage repair foci, faster 
pATM translocation, reduced accumulation of chromosomal 
translocations, but no increase in FancD2 mono-
ubiquitinylation. Global mRNA expression analyses identified 
interferon signaling as a major candidate pathway, which was 
affected by FancA overexpression. Functional interaction 
networks of genes deregulated upon irradiation pointed to 
pathways exclusively involved in FancA-mediated 
radioresistance including the senescence-associated secretory 
phenotype (SASP). Increased levels of basal and irradiation-
induced cellular senescence accompanied by enforced SASP 
formation further support their potential involvement in 
FancA-mediated radiation resistance. The clinical relevance 
of our findings was validated in the data of 113 radiotherapy-
treated patients of the TCGA HNSCC cohort demonstrating 
the association of chromosomal gains on 16q24.3 with 
increased FancA mRNA expression levels and impaired overall 
survival. Furthermore, the translation of our in vitro model 
derived results into the HNSCC patient specimens revealed 
similar gene expression changes linked to FancA 
overexpression. 
 
Conclusion: Our data suggest an important role for FancA in 
cellular mechanisms of radioresistance in HNSCC. 
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Purpose or Objective: The addition of hypoxia modifiers 
carbogen and nicotinamide (CON) to radiotherapy (RT) 
improved overall survival in bladder cancer patients enrolled 
in the BCON phase III clinical trial. We investigated whether 
the expression of miR-210 in the BCON patient samples 
reflects hypoxia and predicts benefit from hypoxia-
modification. 
 
Material and Methods: The retrospective study involved 183 
T1-T4b patients: 86 received RT+CON and 97 received RT 
alone. Formalin-fixed samples taken prior to radiotherapy 
were available and RNA extracted. Customised TaqMan plates 
were used to assess miR-210 expression using quantitative 
real-time PCR. Patients were classified as low miR-210 
(<median expression) or high miR-210 (≥ median). Data on 
other hypoxia biomarkers were available for comparison. 
 
Results: Patients with high miR-210 had a trend towards 
improved five-year OS with RT+CON (53.2%) compared with 
RT alone (37.8%; HR 1.68, 95% CI 0.95-2.95, P=0.08). No 
benefit was seen with low miR-210 (HR 1.02, 95% CI 0.58-
1.79, P=0.97). High expression of miR-210 was also associated 
with high HIF-1α protein (P=0.0008), CA9 protein (P=0.004), 
Glut-1 protein (P=0.02), expression of a 26-gene hypoxia 
signature (P=0.01), tumour necrosis (P=0.04) and concurrent 
pTis (P=0.03). 
 
Conclusion: High miR-210 expression may reflect tumour 
hypoxia and should be investigated further as a potential 
biomarker to identify bladder cancer patients who would 
benefit from hypoxia-modifying therapies. 
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Purpose or Objective: The DNA cytosine deaminase APOBEC3 
proteins catalyze deamination of cytidines in single-stranded 
DNA, providing innate protection against retroviral 
replication. Recent studies have implicated APOBEC3B as a 
major source of mutation in breast cancer, suggesting a role 
for these enzymes in tumor initiation and/or progression. 
APOBEC3B expression levels were earlier found to correlate 
with poor outcomes for patients with estrogen receptor 
positive breast cancer, especially after Tamoxifen. Given its 
role in mutagenesis, we set out to assess whether APOBEC3B 
associates with radiosensitivity in breast cancer. 
 
Material and Methods: MCF7 breast cancer cells were 
cultured radioresistant by daily 2 Gy treatments or 
tamoxifen-resistant by continuous culturing in up to 10 uM 4-
OH-tamoxifen. The effect of irradiation on expression of 
APOBECs was assessed by RNAseq and qPCR in radiosensitive 
and radioresistant MCF7, and by qPCR in radioresistant MDA-
MB231 cells. Furthermore, we studied a retrospective cohort 
of 535 non-systemically treated breast cancer patients. The 
predictive power of APOBEC3B was assessed in patients that 
did or did not receive radiotherapy as part of their primary 
therapy. Next, we suppressed endogenous APOBEC3B in MCF-
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7L with shRNA, or overexpressed either wt APOBEC3B, or a 
catalytically dead mutant APOBEC3B. 
 
Results: Radioresistant breast cancer cells had increased 
baseline APOBEC3B mRNA levels (and not of any of the other 
APOBEC proteins), and irradiation induced an increase in 
APOBEC3B expression in both MCF7 and MDA-MB231 cells. In 
the breast cancer patient cohort we found a strong, 
statistically significant, independent interaction between 
APOBEC3B expression and radiotherapy. APOBEC3B predicted 
a poor prognosis only in those patients that received 
radiotherapy as part of their primary treatment, also when 
this analysis was restricted to patients that received a 
mastectomy (figure). This suggests that APOBEC3B influences 
radiosensitivity, and does not merely predict efficacy of 
surgery (as radiotherapy is generally given to lumpectomy 
patients). The effect of APOBEC3B knockdown and 
overexpression on radiosensitivity is currently being assessed 
using colony-forming assays and will be presented. 
 
 
Conclusion: Our data suggest that the anti-viral APOBEC3B 
enzyme influences radiosensitivity in breast cancer, and 
might be a potential target for radiosensitization. 
 
Proffered Papers: Clinical 9: SBRT and oligometastatic 
disease  
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Purpose or Objective: To determine the radiographic 
response of Hepatocellular Carcinoma (HCC) lesions treated 
via stereotactic body radiotherapy (SBRT) in a series of liver 
transplant candidates and to correlate these findings with 
pathology after transplant. 
 
Material and Methods: We retrospectively reviewed 17 liver 
transplant candidates from December 2008 to December 2013 
at a single institution with discrete HCC lesions were treated 
with SBRT for evaluation of local control (LC); other methods 
of bridging patients to transplant were also available. 
Peripheral SBRT dose was either 50 Gy in 5 fractions or 45 Gy 
in 3 fractions with 2 fractions weekly. The records of 
transplant patients who underwent SBRT for single or 
multiple hepatomas were reviewed for maximum tumor 
dimension (MTD) at time of simulation, last imaging before 
transplant, and gross pathology following transplant. 
Radiographic LC of the treated lesion was defined as stable 
or decreasing enhancement on imaging with either triple-
phase CT Liver or MRI Liver prior to transplant as 
demonstrated in Figure 1; this was recorded one month 
subsequent to treatment and just before the transplant. 
Pathologic Control (PC) was defined as stable to decreased 
size in MTD and/or no viable tumor present. 
 
 
 
Results: Twelve patients have successfully been 
transplanted. All patients were male with a median age of 57 
years. Of the 12 patients transplanted, there were 17 lesions 
treated. Median MTD at time of radiation was 3.6 cm (1.1cm 
- 6.1 cm). Median time to transplant from radiation 
treatment for 12 patients was 9 months (2mo-18mo). Table 1 
summarizes tumor and treatment characteristics. Eight 
lesions (47%) had no evidence of viable tumor on pathology. 
Radiographic LC and PC was achieved in all 17 lesions. At a 
median follow-up of 53 months, disease free and overall 
survival were 100% with no evidence of disease (NED). Of the 
remaining 5 candidates, 3 patients awaiting transplant had 
one lesion, 1 had two lesions, and 1 had three lesions treated 
via SBRT. No patient experienced significant decrement in 
liver function nor indication of radiation induced liver 
disease. One patient experienced Grade 1 abdominal pain 
and three patients experienced Grade 1 nausea. 
 
 
 
Conclusion: SBRT for HCC lesions in transplant candidates is 
an effective means of LC with successful bridging to 
transplant. Radiologic assessment subsequent to SBRT 
correlated with pathologic findings after transplant. These 
promising results suggest a broader role for SBRT in 
management of limited volume HCC. 
 
 
 
 
 
